Serious thrombocytopenia due to dengue hemorrhagic fever treated with high dosages of immunoglobulin [1]

Clinical Infectious Diseases

Volumn 36, Issue 12, 2003, Pages 1623-1624

  Ostronoff, M ^a   Ostronoff, Fabiana ^a,b   Florencio R ^a   Florencio M ^a   Domingues, M C ^a   Calixto, R ^a   Sucupira, A ^a   Souto Maior, A P ^a   Matias, C ^a   Matias, K ^a   Tagliari, C ^a   Soussain, C ^a  

^a Real Hospital Portugues   (Brazil)

^b NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

ADULT; AGED; CLINICAL ARTICLE; DENGUE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; FEMALE; HUMAN; IMMUNE MEDIATED INJURY; IMMUNOTHERAPY; LETTER; MORTALITY; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; CASE REPORT; DENGUE VIRUS; DRUG EFFECT; MIDDLE AGED; PREGNANCY;

ADULT; AGED; DENGUE HEMORRHAGIC FEVER; DENGUE VIRUS; FEMALE; HUMANS; IMMUNOGLOBULINS; MIDDLE AGED; PREGNANCY; THROMBOCYTOPENIA;

EID: 0038209455     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/374870     Document Type: Letter

References (5)

1. Guzmán MG, Kourí G. Dengue: an update. Lancet Infect Dis 2002; 2:33-42.
2. Imbach P. Immune thrombocytopenic purpura and intravenous immunoglobulin. Cancer 1991; 68:1422-5.
3. Shulman ST. IVIG therapy in Kawasaki disease: a mechanism(s) of action. Clin Immunol Immunopathol 1989; 53:S141-6.
4. World Health Organization. Dengue and dengue haemorrhagic fever. Available at: http://www.who.int/inf-fs/en/fact_117.html.Accessed 19 August 2002.
5. Qureshi JA, Notta NJ, Salahuddin N, Zaman V, Khan JA. An epidemic of dengue fever in Karachi- associated clinical manifestations. J Pak Med Assoc 1997; 47:178-81.